Peritoneal carcinomatosis (PC) of colorectal cancer (CRC) origin is associated with poor outcome. This systematic review evaluates the available evidence about adjuvant (hyperthermic) intraperitoneal chemotherapy ((H)IPEC) to prevent the development of PC.status: publishe
Several gastrointestinal and gynecological malignancies have the potential to disseminate and grow i...
Approximately 5% of colorectal cancer (CRC) patients will develop peritoneal carcinomatosis (PC) in ...
Full list of author information is available at the end of the articleof outgrowth of peritoneal mic...
Peritoneal carcinomatosis (PC) of colorectal cancer (CRC) origin is associated with poor outcome. Th...
textabstractBackground: The peritoneum is the second most common site of recurrence in colorectal ca...
Background: Today, we do not have a universally accepted evidence on how to treat peritoneal carcino...
Contains fulltext : 109022.pdf (publisher's version ) (Open Access)Peritoneal carc...
Oxaliplatin and Mitomycin C (MMC) are both suitable as intraperitoneal chemotherapy agents in HIPEC ...
OBJECTIVE: To review the literature with regard to the incidence and prognostic significance of peri...
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a minimally invasive approach under inve...
Abstract: Peritoneal carcinomatosis (PC) was previously considered an incurable disease with a poor ...
Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction...
Complete cytoreductive surgery (CCRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) is the ...
Perioperative intraperitoneal chemotherapy in combination with cytoreductive surgery has been shown ...
Twelve to 13% of patients with colorectal cancer (CRC) develop peritoneal carcinomatosis (PC), the m...
Several gastrointestinal and gynecological malignancies have the potential to disseminate and grow i...
Approximately 5% of colorectal cancer (CRC) patients will develop peritoneal carcinomatosis (PC) in ...
Full list of author information is available at the end of the articleof outgrowth of peritoneal mic...
Peritoneal carcinomatosis (PC) of colorectal cancer (CRC) origin is associated with poor outcome. Th...
textabstractBackground: The peritoneum is the second most common site of recurrence in colorectal ca...
Background: Today, we do not have a universally accepted evidence on how to treat peritoneal carcino...
Contains fulltext : 109022.pdf (publisher's version ) (Open Access)Peritoneal carc...
Oxaliplatin and Mitomycin C (MMC) are both suitable as intraperitoneal chemotherapy agents in HIPEC ...
OBJECTIVE: To review the literature with regard to the incidence and prognostic significance of peri...
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a minimally invasive approach under inve...
Abstract: Peritoneal carcinomatosis (PC) was previously considered an incurable disease with a poor ...
Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction...
Complete cytoreductive surgery (CCRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) is the ...
Perioperative intraperitoneal chemotherapy in combination with cytoreductive surgery has been shown ...
Twelve to 13% of patients with colorectal cancer (CRC) develop peritoneal carcinomatosis (PC), the m...
Several gastrointestinal and gynecological malignancies have the potential to disseminate and grow i...
Approximately 5% of colorectal cancer (CRC) patients will develop peritoneal carcinomatosis (PC) in ...
Full list of author information is available at the end of the articleof outgrowth of peritoneal mic...